Protocol Ledger

NCT05596409 · Phase II · ACTIVE NOT RECRUITING

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Interventional Phase II clinical trial protocol NCT05596409 sponsored by Stemline Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-19 Enrollment: 61 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05596409
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)61 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05596409
Protocol FieldVerified Registry Value
NCT IdentifierNCT05596409
Consolidated Lead SponsorStemline Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment61 participants (ACTUAL)
Registered Start Date2023-05-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05596409
Hospital Research SiteLocationSite Profile
Northwestern Memorial and Lurie Cancer CenterChicago, ILOpen Hospital Dossier ->
Comprehensive Cancer Centers of NevadaLas Vegas, NVOpen Hospital Dossier ->
Hospital de Clinicas de Porto AlegrePorto Alegre, BrazilOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI